胃肠道腺癌患者的血清血管活性肠肽（VIP）水平。

Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract.

作者信息

Hejna M, Hamilton G, Brodowicz T, Haberl I, Fiebiger W C, Scheithauer W, Virgolini I, Köstler W J, Oberhuber G, Raderer M

机构信息

Division of Oncology, University of Vienna, Austria.

出版信息

Anticancer Res. 2001 Mar-Apr;21(2A):1183-7.

PMID:11396161

Abstract

BACKGROUND

VIP acts as a neuroendocrine mediator under physiological conditions, with an important role in water and electrolyte secretion in the gut. Recent findings suggest that VIP also promotes growth and proliferation of normal as well as malignant cells. We have investigated the VIP-serum levels in patients with pancreatic cancer and colonic adenocarcinoma as compared to healthy controls. This was accompanied by immunohistochemical investigations and in vitro experiments to further define the role of the peptide in pancreatic and colorectal cancer.

MATERIALS AND METHODS

Serum levels of VIP were evaluated under standardized conditions in a total of 135 patients; 45 patients had metastatic colorectal cancer, 45 suffered from metastatic pancreatic cancer, and 45 healthy volunteers served as controls. Human pancreatic and colorectal carcinoma cell lines were incubated over 5 days with VIP in increasing concentrations.

RESULTS

In healthy controls, a median VIP-serum level of 42.44 +/- 2.540 pg/ml (range, 12.9-98.5 pg/ml) was found, while patients with pancreatic cancer had a median level of 40.58 +/- 3.013 pg/ml (range, 6.9-102.4 pg/ml). In patients with cancer originating in the colon, however, a median serum level of 116 +/- 10.14 pg/ml (range, 51.6-487 pg/ml) was found. While no difference between healthy controls and patients with pancreatic cancer could be detected (p = 0.6381), a significant difference between patients with colorectal cancer and healthy controls (p < 0.0001) and patients with pancreatic cancer (p < 0.0001) was demonstrated. The median VIP-concentrations found in the patients sera for pancreatic and colonic tumor patient groups, 40 pg/ml and 115 pg/ml respectively, had no significant effect on the proliferation of PANC-1 and HT29, inhibited ASPC-1, BxPC3, COLO201 and HCT-15 cells, and stimulated the growth of one pancreatic (CAPAN-1) and one colonic (COLO320DM) cell line under these conditions.

CONCLUSIONS

As opposed to pancreatic cancer and healthy controls, patients in our series had elevated serum VIP-levels. Further studies are warranted to evaluate whether VIP can be used as a tumor marker in this disease.

摘要

背景

血管活性肠肽（VIP）在生理条件下起神经内分泌介质的作用，在肠道水和电解质分泌中起重要作用。最近的研究结果表明，VIP还能促进正常细胞以及恶性细胞的生长和增殖。我们研究了胰腺癌和结肠腺癌患者与健康对照者的血清VIP水平。同时进行了免疫组化研究和体外实验，以进一步明确该肽在胰腺癌和结直肠癌中的作用。

材料与方法

在标准化条件下，对总共135例患者的血清VIP水平进行了评估；45例患者患有转移性结直肠癌，45例患有转移性胰腺癌，45名健康志愿者作为对照。将人胰腺和结肠癌细胞系与浓度递增的VIP孵育5天。

结果

在健康对照者中，血清VIP的中位水平为42.44±2.540 pg/ml（范围为12.9 - 98.5 pg/ml），而胰腺癌患者的中位水平为40.58±3.013 pg/ml（范围为6.9 - 102.4 pg/ml）。然而，结肠癌患者的血清中位水平为116±10.14 pg/ml（范围为51.6 - 487 pg/ml）。虽然未检测到健康对照者与胰腺癌患者之间存在差异（p = 0.6381），但结直肠癌患者与健康对照者（p < 0.0001）以及与胰腺癌患者（p < 0.0001）之间存在显著差异。在胰腺癌和结肠肿瘤患者组的患者血清中发现的VIP中位浓度分别为40 pg/ml和115 pg/ml，在这些条件下，对PANC - 1和HT29细胞的增殖无显著影响，抑制了ASPC - 1、BxPC3、COLO201和HCT - 15细胞，并刺激了一种胰腺（CAPAN - 1）和一种结肠（COLO320DM）细胞系的生长。